NURS 6521N Advanced Pharmacology Midterm Exam Prep
Document | 2026/2027 Edition | 250 Verified Questions
NURS 6521N Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NURS 6521N Advanced Pharmacology covers the
midterm exam content. It includes 250 verified multiple-choice questions with detailed explanations,
ensuring mastery of key pharmacological principles. Designed for Walden University's 2026/2027
curriculum, it reflects the latest guidelines and best practices in advanced pharmacology. This resource
is essential for nursing students seeking high performance on their midterm.
Abstract:
This document provides a rigorous review of advanced pharmacology concepts essential for the NURS 6521N
midterm exam. It encompasses 250 meticulously verified multiple-choice questions, each accompanied by
comprehensive explanations that clarify both correct and incorrect answer choices. The content is organized into
core areas including pharmacokinetics, drug interactions, and therapeutic applications across major body systems.
Updated for the 2026/2027 academic year, this resource integrates the latest evidence-based guidelines and
pharmacotherapeutic advancements. It serves as a definitive tool for nursing students to achieve mastery and excel
in their midterm assessment.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; Receptor theory; Dose-response
relationships
Autonomic Nervous System 41-70 Cholinergic agonists/antagonists; 12%
Drugs Adrenergic agonists/antagonists; Ganglionic
blockers
Cardiovascular Pharmacology 71-110 Antihypertensives; Antiarrhythmics; 16%
Antianginals; Heart failure drugs
Endocrine and Metabolic Drugs 111-150 Insulin and oral hypoglycemics; Thyroid and 16%
antithyroid; Corticosteroids; Sex hormones
Antimicrobial and Anti-infective 151-180 Antibacterials; Antivirals; Antifungals; 12%
Agents Antiparasitics
Pain Management and CNS 181-210 Opioid and non-opioid analgesics; 12%
Drugs Anesthetics; Antiepileptics;
Psychopharmacology
Oncologic and Immunologic 211-250 Chemotherapy agents; Targeted therapy; 16%
Pharmacology Immunosuppressants; Biologics
Page 1
,Q1. A patient with chronic pain is prescribed codeine but reports minimal analgesic effect.
Genotyping reveals a CYP2D6 poor metabolizer phenotype. Which pharmacokinetic change
primarily explains the lack of efficacy?
A. Rapid renal elimination of codeine
B. Reduced conversion of codeine to morphine
C. Increased first-pass metabolism to inactive glucuronides
D. Enhanced P-glycoprotein efflux at the blood-brain barrier
Correct Answer: B. Reduced conversion of codeine to morphine
Rationale: Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to morphine for
analgesic activity. Poor metabolizers have deficient CYP2D6 activity, resulting in subtherapeutic
morphine concentrations. Other options are not primary mechanisms: renal elimination of codeine is not
the rate-limiting step, first-pass glucuronidation is mediated by UGT enzymes, and P-glycoprotein efflux
is not the key factor for codeine.
Why Wrong:
A - Renal elimination of codeine is not altered in CYP2D6 poor metabolizers.
C - First-pass glucuronidation of codeine is not primarily affected by CYP2D6 status.
D - P-glycoprotein efflux is not directly related to CYP2D6 metabolism of codeine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4, 7
Q2. A patient with heart failure with reduced ejection fraction (HFrEF) is started on carvedilol.
Which property of carvedilol differentiates it from metoprolol in terms of mortality benefit in HF?
A. Cardioselective 1 antagonism
B. Intrinsic sympathomimetic activity
C. Additional 1-adrenergic blockade
D. Greater lipophilicity and central nervous system penetration
Correct Answer: C. Additional 1-adrenergic blockade
Rationale: Carvedilol is a nonselective ²-blocker with additional ±1-blocking activity, which reduces
peripheral vascular resistance and afterload, providing a unique hemodynamic benefit in HF. Metoprolol
is 1-selective. Intrinsic sympathomimetic activity is absent in both and would be detrimental in HF.
Greater lipophilicity does not confer additional mortality benefit.
Why Wrong:
A - Cardioselectivity is a feature of metoprolol, not carvedilol.
B - Neither carvedilol nor metoprolol possesses intrinsic sympathomimetic activity.
D - Lipophilicity is not the distinguishing factor for mortality benefit in HF.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22
Page 2
,Q3. A patient with a severe Gram-negative infection is receiving gentamicin. The infection fails to
clear despite therapeutic serum levels. Which bacterial resistance mechanism most likely explains
this treatment failure?
A. Production of -lactamase
B. Alteration of the 30S ribosomal subunit target
C. Efflux pump overexpression reducing intracellular drug concentration
D. Enzymatic acetylation, phosphorylation, or adenylation of the drug
Correct Answer: D. Enzymatic acetylation, phosphorylation, or adenylation of the drug
Rationale: The most common acquired resistance to aminoglycosides like gentamicin is enzymatic
modification by bacterial aminoglycoside-modifying enzymes (acetylation, phosphorylation, adenylation).
This is distinct from -lactamase (inactivates -lactams), target alteration (seen with macrolides), or efflux
(less common for aminoglycosides).
Why Wrong:
A - -lactamase production inactivates -lactams, not aminoglycosides.
B - Target alteration is a mechanism for macrolide resistance, not primary for aminoglycosides.
C - Efflux pumps contribute but are not the dominant resistance mechanism for aminoglycosides.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 78
Q4. A patient with severe pain controlled on morphine sulfate 15 mg every 4 hours (360 mg/day oral
morphine equivalent) is to be rotated to hydromorphone. Current evidence indicates incomplete
cross-tolerance. Which conversion factor is most appropriate to account for incomplete
cross-tolerance?
A. Use the equianalgesic ratio directly (oral hydromorphone 7.5 mg/24 hr per 30 mg morphine)
B. Reduce the calculated dose by 25-50%
C. Increase the calculated dose by 25%
D. Maintain the same dose but switch route to intravenous
Correct Answer: B. Reduce the calculated dose by 25-50%
Rationale: Incomplete cross-tolerance between opioids requires a dose reduction of 25–50% from the
equianalgesic calculated dose when rotating to a new opioid, to prevent toxicity. Using the ratio directly
(option A) risks overdose, increasing the dose (C) is incorrect, and route change without dose adjustment
(D) is not a standard cross-tolerance strategy.
Why Wrong:
A - Direct use of the equianalgesic ratio does not account for incomplete cross-tolerance, risking
overdose.
C - Increasing the dose would compound the risk of incomplete cross-tolerance and toxicity.
D - Route change alone does not address cross-tolerance; dose adjustment is still needed.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 12, 13
Page 3
, Q5. A patient on a selective serotonin reuptake inhibitor (SSRI) is started on linezolid for a skin
infection. Within days, the patient develops hyperthermia, agitation, and clonus. Which mechanism
explains this interaction?
A. Linezolid inhibits monoamine oxidase, increasing synaptic serotonin
B. SSRI increases linezolid metabolism via CYP450 induction
C. Linezolid displaces SSRI from plasma proteins, raising free drug
D. SSRI potentiates the antibacterial effect of linezolid
Correct Answer: A. Linezolid inhibits monoamine oxidase, increasing synaptic serotonin
Rationale: Linezolid is a reversible nonselective monoamine oxidase inhibitor (MAOI). When combined
with an SSRI, it inhibits serotonin breakdown, precipitating serotonin syndrome. Option B is incorrect
because linezolid is not metabolized by CYP450; it undergoes oxidation via non-CYP pathways. Option C
(protein displacement) does not cause serotonin syndrome. Option D is not a drug interaction leading to
serotonin toxicity.
Why Wrong:
B - Linezolid metabolism is not significantly affected by CYP450; this is not the mechanism.
C - Protein displacement would not produce hyperthermia and clonus characteristic of serotonin
syndrome.
D - SSRI does not potentiate linezolid's antibacterial effect in a manner causing serotonin syndrome.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 80
Q6. A patient with type 2 diabetes is started on insulin glargine. Which property of glargine
accounts for its relatively flat, peakless pharmacokinetic profile compared to NPH insulin?
A. Addition of zinc to delay absorption
B. Protamine Hagedorn formulation
C. pH-dependent precipitation at injection site
D. Addition of fatty acid side chain for albumin binding
Correct Answer: C. pH-dependent precipitation at injection site
Rationale: Insulin glargine is soluble at acidic pH but precipitates in the neutral pH of subcutaneous
tissue, forming microprecipitates that slowly release insulin, producing a flat profile. NPH insulin uses
protamine to prolong duration but has a peak. Zinc addition is used in zinc insulins (e.g., Lente) but not
glargine. Fatty acid side chains are used in detemir and degludec.
Why Wrong:
A - Zinc is added to some insulin preparations (e.g., NPH contains zinc), but glargine's mechanism is
pH precipitation, not zinc.
B - Protamine Hagedorn is the formulation of NPH, not glargine.
D - Fatty acid side chains are features of insulin detemir and degludec, not glargine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 44
Page 4
Document | 2026/2027 Edition | 250 Verified Questions
NURS 6521N Advanced Pharmacology Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NURS 6521N Advanced Pharmacology covers the
midterm exam content. It includes 250 verified multiple-choice questions with detailed explanations,
ensuring mastery of key pharmacological principles. Designed for Walden University's 2026/2027
curriculum, it reflects the latest guidelines and best practices in advanced pharmacology. This resource
is essential for nursing students seeking high performance on their midterm.
Abstract:
This document provides a rigorous review of advanced pharmacology concepts essential for the NURS 6521N
midterm exam. It encompasses 250 meticulously verified multiple-choice questions, each accompanied by
comprehensive explanations that clarify both correct and incorrect answer choices. The content is organized into
core areas including pharmacokinetics, drug interactions, and therapeutic applications across major body systems.
Updated for the 2026/2027 academic year, this resource integrates the latest evidence-based guidelines and
pharmacotherapeutic advancements. It serves as a definitive tool for nursing students to achieve mastery and excel
in their midterm assessment.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion; Receptor theory; Dose-response
relationships
Autonomic Nervous System 41-70 Cholinergic agonists/antagonists; 12%
Drugs Adrenergic agonists/antagonists; Ganglionic
blockers
Cardiovascular Pharmacology 71-110 Antihypertensives; Antiarrhythmics; 16%
Antianginals; Heart failure drugs
Endocrine and Metabolic Drugs 111-150 Insulin and oral hypoglycemics; Thyroid and 16%
antithyroid; Corticosteroids; Sex hormones
Antimicrobial and Anti-infective 151-180 Antibacterials; Antivirals; Antifungals; 12%
Agents Antiparasitics
Pain Management and CNS 181-210 Opioid and non-opioid analgesics; 12%
Drugs Anesthetics; Antiepileptics;
Psychopharmacology
Oncologic and Immunologic 211-250 Chemotherapy agents; Targeted therapy; 16%
Pharmacology Immunosuppressants; Biologics
Page 1
,Q1. A patient with chronic pain is prescribed codeine but reports minimal analgesic effect.
Genotyping reveals a CYP2D6 poor metabolizer phenotype. Which pharmacokinetic change
primarily explains the lack of efficacy?
A. Rapid renal elimination of codeine
B. Reduced conversion of codeine to morphine
C. Increased first-pass metabolism to inactive glucuronides
D. Enhanced P-glycoprotein efflux at the blood-brain barrier
Correct Answer: B. Reduced conversion of codeine to morphine
Rationale: Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to morphine for
analgesic activity. Poor metabolizers have deficient CYP2D6 activity, resulting in subtherapeutic
morphine concentrations. Other options are not primary mechanisms: renal elimination of codeine is not
the rate-limiting step, first-pass glucuronidation is mediated by UGT enzymes, and P-glycoprotein efflux
is not the key factor for codeine.
Why Wrong:
A - Renal elimination of codeine is not altered in CYP2D6 poor metabolizers.
C - First-pass glucuronidation of codeine is not primarily affected by CYP2D6 status.
D - P-glycoprotein efflux is not directly related to CYP2D6 metabolism of codeine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 4, 7
Q2. A patient with heart failure with reduced ejection fraction (HFrEF) is started on carvedilol.
Which property of carvedilol differentiates it from metoprolol in terms of mortality benefit in HF?
A. Cardioselective 1 antagonism
B. Intrinsic sympathomimetic activity
C. Additional 1-adrenergic blockade
D. Greater lipophilicity and central nervous system penetration
Correct Answer: C. Additional 1-adrenergic blockade
Rationale: Carvedilol is a nonselective ²-blocker with additional ±1-blocking activity, which reduces
peripheral vascular resistance and afterload, providing a unique hemodynamic benefit in HF. Metoprolol
is 1-selective. Intrinsic sympathomimetic activity is absent in both and would be detrimental in HF.
Greater lipophilicity does not confer additional mortality benefit.
Why Wrong:
A - Cardioselectivity is a feature of metoprolol, not carvedilol.
B - Neither carvedilol nor metoprolol possesses intrinsic sympathomimetic activity.
D - Lipophilicity is not the distinguishing factor for mortality benefit in HF.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 22
Page 2
,Q3. A patient with a severe Gram-negative infection is receiving gentamicin. The infection fails to
clear despite therapeutic serum levels. Which bacterial resistance mechanism most likely explains
this treatment failure?
A. Production of -lactamase
B. Alteration of the 30S ribosomal subunit target
C. Efflux pump overexpression reducing intracellular drug concentration
D. Enzymatic acetylation, phosphorylation, or adenylation of the drug
Correct Answer: D. Enzymatic acetylation, phosphorylation, or adenylation of the drug
Rationale: The most common acquired resistance to aminoglycosides like gentamicin is enzymatic
modification by bacterial aminoglycoside-modifying enzymes (acetylation, phosphorylation, adenylation).
This is distinct from -lactamase (inactivates -lactams), target alteration (seen with macrolides), or efflux
(less common for aminoglycosides).
Why Wrong:
A - -lactamase production inactivates -lactams, not aminoglycosides.
B - Target alteration is a mechanism for macrolide resistance, not primary for aminoglycosides.
C - Efflux pumps contribute but are not the dominant resistance mechanism for aminoglycosides.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 78
Q4. A patient with severe pain controlled on morphine sulfate 15 mg every 4 hours (360 mg/day oral
morphine equivalent) is to be rotated to hydromorphone. Current evidence indicates incomplete
cross-tolerance. Which conversion factor is most appropriate to account for incomplete
cross-tolerance?
A. Use the equianalgesic ratio directly (oral hydromorphone 7.5 mg/24 hr per 30 mg morphine)
B. Reduce the calculated dose by 25-50%
C. Increase the calculated dose by 25%
D. Maintain the same dose but switch route to intravenous
Correct Answer: B. Reduce the calculated dose by 25-50%
Rationale: Incomplete cross-tolerance between opioids requires a dose reduction of 25–50% from the
equianalgesic calculated dose when rotating to a new opioid, to prevent toxicity. Using the ratio directly
(option A) risks overdose, increasing the dose (C) is incorrect, and route change without dose adjustment
(D) is not a standard cross-tolerance strategy.
Why Wrong:
A - Direct use of the equianalgesic ratio does not account for incomplete cross-tolerance, risking
overdose.
C - Increasing the dose would compound the risk of incomplete cross-tolerance and toxicity.
D - Route change alone does not address cross-tolerance; dose adjustment is still needed.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 12, 13
Page 3
, Q5. A patient on a selective serotonin reuptake inhibitor (SSRI) is started on linezolid for a skin
infection. Within days, the patient develops hyperthermia, agitation, and clonus. Which mechanism
explains this interaction?
A. Linezolid inhibits monoamine oxidase, increasing synaptic serotonin
B. SSRI increases linezolid metabolism via CYP450 induction
C. Linezolid displaces SSRI from plasma proteins, raising free drug
D. SSRI potentiates the antibacterial effect of linezolid
Correct Answer: A. Linezolid inhibits monoamine oxidase, increasing synaptic serotonin
Rationale: Linezolid is a reversible nonselective monoamine oxidase inhibitor (MAOI). When combined
with an SSRI, it inhibits serotonin breakdown, precipitating serotonin syndrome. Option B is incorrect
because linezolid is not metabolized by CYP450; it undergoes oxidation via non-CYP pathways. Option C
(protein displacement) does not cause serotonin syndrome. Option D is not a drug interaction leading to
serotonin toxicity.
Why Wrong:
B - Linezolid metabolism is not significantly affected by CYP450; this is not the mechanism.
C - Protein displacement would not produce hyperthermia and clonus characteristic of serotonin
syndrome.
D - SSRI does not potentiate linezolid's antibacterial effect in a manner causing serotonin syndrome.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16, 80
Q6. A patient with type 2 diabetes is started on insulin glargine. Which property of glargine
accounts for its relatively flat, peakless pharmacokinetic profile compared to NPH insulin?
A. Addition of zinc to delay absorption
B. Protamine Hagedorn formulation
C. pH-dependent precipitation at injection site
D. Addition of fatty acid side chain for albumin binding
Correct Answer: C. pH-dependent precipitation at injection site
Rationale: Insulin glargine is soluble at acidic pH but precipitates in the neutral pH of subcutaneous
tissue, forming microprecipitates that slowly release insulin, producing a flat profile. NPH insulin uses
protamine to prolong duration but has a peak. Zinc addition is used in zinc insulins (e.g., Lente) but not
glargine. Fatty acid side chains are used in detemir and degludec.
Why Wrong:
A - Zinc is added to some insulin preparations (e.g., NPH contains zinc), but glargine's mechanism is
pH precipitation, not zinc.
B - Protamine Hagedorn is the formulation of NPH, not glargine.
D - Fatty acid side chains are features of insulin detemir and degludec, not glargine.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 44
Page 4
